MEDI 6570
Alternative Names: MEDI-6570; MEI-6570Latest Information Update: 09 May 2024
At a glance
- Originator MedImmune
- Developer AstraZeneca
- Class Antihyperlipidaemics; Cardiovascular therapies
- Mechanism of Action Oxidised low density lipoprotein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atherosclerosis; Coronary disorders
Most Recent Events
- 25 Apr 2024 Discontinued - Phase-I for Atherosclerosis in USA (SC) (AstraZeneca pipeline, May 2024)
- 25 Apr 2024 Discontinued - Phase-II for Atherosclerosis in Hungary (SC) (AstraZeneca pipeline, May 2024)
- 25 Apr 2024 Discontinued - Phase-II for Coronary disorders in USA, Netherlands, Australia, Canada, Italy, Spain, Poland, United Kingdom, Hungary, Czech Republic, Japan (SC) (AstraZeneca pipeline, May 2024)